RecentObservational

Immunosuppression during transplant sepsis

Immunosuppressive therapy management during sepsis in kidney transplant recipients: a prospective multicenter study.

Annals of Intensive Care, 2025 · Prospective cohort across 11 French ICUs

Population: 124 kidney-transplant recipients transplanted ≥3 months previously and admitted for sepsis
Intervention: Observed immunosuppression discontinuation
Comparator: Observed continuation
Primary outcome: Major adverse kidney events at 180 days
Result: Mycophenolic-acid discontinuation associated with MAKE180: adjusted OR 1.45 (1.07–1.96).

What the trial found

Association between MPA discontinuation and adverse outcomes; no randomized treatment comparison.

Clinical interpretation

Confounding and COVID-specific protocols limit causality. Neither mandatory continuation nor blanket withdrawal is established; individualize with transplant specialists.

Low certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Kidney Transplantation in the ICU

ICU care of the kidney-transplant recipient: allograft dysfunction, vascular/urologic emergencies, rejection, infection, immunosuppression toxicity and renal replacement decisions

View Topic Context →